Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. - Wikidata - awgldk - TriplyDB

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

http://www.wikidata.org/entity/Q30407589

about

Time to change the blind men and the elephant approach to Parkinson disease?Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.Sex Differences in Clinical Features of Early, Treated Parkinson's Disease.Bayesian multivariate augmented Beta rectangular regression models for patient-reported outcomes and survival data.Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term S The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease.Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Augmented Beta rectangular regression models: A Bayesian perspective Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort.The CREST-E study of creatine for Huntington disease: A randomized controlled trial.Outcome measurement in neurodegenerative disease: attributes, applications & interpretation.Advances in clinical trials for movement disorders.A predictive model to identify Parkinson disease from administrative claims data.Decade in review-movement disorders: tracking the pathogenesis of movement disorders.Creatine for neuroprotection in neurodegenerative disease: end of story?Therapeutic approaches in Parkinson's disease and related disorders.Beyond muscles: The untapped potential of creatine.Potential of creatine or phosphocreatine supplementation in cerebrovascular disease and in ischemic heart disease.New and emerging medical therapies in Parkinson's disease.Structural correlates of the creatine transporter function regulation: the undiscovered country.Communicating with participants during the conduct of multi-center clinical trials.Caffeine, creatine, GRIN2A and Parkinson's disease progression.Current and experimental treatments of Parkinson disease: A guide for neuroscientists.Creatine and creatine forms intended for sports nutrition.Precision medicine for disease modification in Parkinson disease.Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.The role of Ca2+ signaling in Parkinson's disease.Targeting urate to reduce oxidative stress in Parkinson disease.Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort.Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1.Autonomic and electrocardiographic findings in Parkinson's disease.Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores.Mitochondrial DNA depletion by ethidium bromide decreases neuronal mitochondrial creatine kinase: Implications for striatal energy metabolism.

P2860

Q27693350-E14B74B6-C3FE-4533-869D-68B99CA66E15 Q28084254-BC378586-C120-4A29-A0F4-2CD73CE42BAC Q30357397-4266EF00-1D6A-40EE-9F4D-7C4FE9420F93 Q30375563-701E2609-0BA6-477E-B7ED-4A7761EA810B Q30964183-3BA79885-11B7-414F-A941-3A4F26BC4D15 Q31036167-FDC42329-23ED-43D1-93CB-EB280BEF73CC Q33760040-9CB2CEAF-16CD-49FA-AADF-538AB8B49267 Q33788172-BED9FB8A-E870-4E07-AD49-61FAA6084435 Q36070544-0284C69F-9B1B-49D9-83A7-87E1352574A1 Q36164724-70A89106-5DEA-4A4B-B371-87FC147B896B Q36372732-4D371E7F-50A8-4C0F-A3D5-03F5CB86BDBF Q36387048-846C8100-54B8-4E67-843E-3FD86BBCE227 Q36925905-B1F2F8D1-D93F-4068-B883-E20564789B54 Q37340669-9239065C-B1BA-494D-B6A0-B96F593055F3 Q38373893-F97EB4CB-FFEA-4BA8-A461-2A0A016FEC2C Q38374092-D4383E2D-26EE-48F7-9589-08575C121EB4 Q38570993-BEAF338C-4E6B-4049-A578-B97AF70E1714 Q38573937-56E88897-C2F2-4D3E-A406-F10B2C476E49 Q38597211-691575D5-C83B-4EC7-A82E-288D722A028B Q38616824-FDB45381-16B9-4570-9CFD-E185072421B3 Q38691246-8CD8C96F-7962-4631-84E8-F056CEA1C52F Q38691406-DCE44B8B-FF39-41FF-AB4E-039EE3515395 Q38700215-3C336658-58ED-46DC-99D2-3A7DDE0059CE Q38706110-E24E0765-22A0-4AA5-BAF4-F8A26C9BE0B9 Q38718194-80F193E0-F204-48CF-AECB-992F632C5F3B Q38764046-A5308A0D-232C-4480-B9B5-D26159CE6ABA Q38826602-E06B2C4D-24DC-419C-A902-C42F2494665C Q38893103-EE60BF89-68DB-4B8F-997A-321541D4F380 Q38941557-8F10CECF-0988-4ACD-87A2-DA585FA7B41F Q39055380-64370D8F-23EF-4CC2-9429-DBF155CCBE81 Q39096323-1CC419AF-D4C1-460E-B00C-074DB5E39526 Q39199926-A8188EA1-FC52-4F1E-AD77-68776B937F0F Q39281423-05848A3B-8150-4526-89FF-18AD89382358 Q39379023-DA4F174C-3F6C-460C-9D77-C421BD35A188 Q40240247-315E966B-BD05-4A82-A5C9-411D31F8A305 Q40540982-CF885DA8-AC76-4FE0-A6B6-396A414744E5 Q45228075-CBCEBDEF-054B-4302-A9CE-A0D3D2D4B3BE Q46004015-D52600A4-C90D-46DF-8330-0EABCDEFD93C Q46184142-1D897FF0-3F12-4249-9782-2DC5EF4F6816 Q47233980-E4E01C81-2E83-4E13-B592-C2B26F380C44

P2860

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

http://www.wikidata.org/entity/Q30407589

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Effect of creatine monohydrate ...... : a randomized clinical trial.

@ast

Effect of creatine monohydrate ...... : a randomized clinical trial.

@en

type

label

Effect of creatine monohydrate ...... : a randomized clinical trial.

@ast

Effect of creatine monohydrate ...... : a randomized clinical trial.

@en

prefLabel

Effect of creatine monohydrate ...... : a randomized clinical trial.

@ast

Effect of creatine monohydrate ...... : a randomized clinical trial.

@en

P1433

Q30407589-B3307760-73C6-4994-A25A-F27FF6C91311

P1476

Q30407589-3C28F121-FEAE-40C0-B9EB-484BACA4049A

P2093

Q30407589-064EDF57-C9E1-4339-A969-8C5304811126

Q30407589-121F0FA6-71C3-4800-AE70-DC422B5D5055

Q30407589-1703DF13-0FAA-4C3E-8C51-75590351A146

Q30407589-1B1F37CA-6492-48B1-8FA0-EC963BE5713D

Q30407589-22B48579-CF97-4D61-8C31-7DD85C0E0BE4

Q30407589-243DBE79-7B73-4452-A69B-7E65FDC3C627

Q30407589-297E4AFD-D223-455B-AE91-37219EE96603

Q30407589-2A75C4FF-B9AD-4A18-B73D-B38034F0A323

Q30407589-2D344E26-50AA-4059-8748-9B6ABA173DC3

Q30407589-2EF177AB-162E-42A6-9603-6ECCF5D8DB07

P2860

Q30407589-017F49C3-4A2A-48FF-B175-4C5F00ACFD45

Q30407589-117D6705-C6E0-4C37-B585-C0B6847DBEE7

Q30407589-248AFAA9-8177-42CB-9CC7-5E028387DE31

Q30407589-38797E84-EFD7-4E3F-9172-01CC0BFE2C91

Q30407589-40265886-DC7B-44D8-874E-48C1501EC974

Q30407589-4752084D-5A04-4932-B0F5-2CBF7B6FA797

Q30407589-47CD0C88-3992-4281-A7A7-9DF48B38EA3C

Q30407589-4A2EB97C-75D5-41AC-BAB6-97DADF15BE2F

Q30407589-4E803F22-D2F0-4A93-B5AF-35D197E344AF

Q30407589-5295D82A-44EF-4627-B765-1B3A495942A6

P304

Q30407589-2CD74953-9C5C-4CEA-A0C6-85B4F1448619

P31

Q30407589-7182CD1A-CBA9-4499-B66B-BD5C532A5B46

P356

Q30407589-C430106C-A074-493E-82D8-A0FB1E52521F

P407

Q30407589-009D685E-3E57-4C06-BD8B-F549B24E4C02

P433

Q30407589-732B6392-7388-42C8-9689-A207A5B07A8F

P478

Q30407589-A429402A-FE7A-40DD-8C93-7FD529C24512

P50

Q30407589-24B4052B-5F56-445D-B438-6CA2A75E3F29

Q30407589-2AB054D0-93F7-464D-8644-E5E10C6EB69E

Q30407589-5109BCBE-902F-4DAA-9F88-33CD180C66C1

Q30407589-B3E324C1-C007-43A4-B03A-E8CD6A38700D

Q30407589-C6614491-6FB2-4D53-A21D-DD18C59F947B

Q30407589-CDDDEE74-2EB3-498B-A526-87ADF476BD0D

P577

Q30407589-D80BDAE9-D723-4455-BDFC-F1F19B0CF492

P5875

Q30407589-F78172C3-7EF2-4F3F-A7C8-71F03D4D7E4A

P698

Q30407589-3F167798-9E7C-4D8E-885E-A0D18D278940

P921

Q30407589-D1B591D2-A417-4AEF-B0CF-207900CA560D

P932

Q30407589-A40EC731-14C0-4CCF-9B4E-DCBD62F23C0A

P356

P1433

Journal of the American Medical Association

P1476

Effect of creatine monohydrate ...... : a randomized clinical trial.

@en

P2093

Alicia H Augustine

http://www.w3.org/2001/XMLSchema#string

Anne-Marie Wills

http://www.w3.org/2001/XMLSchema#string

Barbara C Tilley

http://www.w3.org/2001/XMLSchema#string

Carlos Singer

http://www.w3.org/2001/XMLSchema#string

Chadwick W Christine

http://www.w3.org/2001/XMLSchema#string

Chizoba C Umeh

http://www.w3.org/2001/XMLSchema#string

Cornelia Kamp

http://www.w3.org/2001/XMLSchema#string

David J Houghton

http://www.w3.org/2001/XMLSchema#string

David K Simon

http://www.w3.org/2001/XMLSchema#string

Debra Babcock

http://www.w3.org/2001/XMLSchema#string

P2860

EuroQol--a new facility for the measurement of health-related quality of life

A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results

Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.

Cross-cultural evaluation of the Parkinson's Disease Questionnaire: tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain.

Using global statistical tests in long-term Parkinson's disease clinical trials.

Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem

Interobserver agreement for the assessment of handicap in stroke patients.

Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.

P304

584-593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2015.120

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

313

http://www.w3.org/2001/XMLSchema#string

P50

Robert A Hauser

Caroline M Tanner

Nabila Dahodwala

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272192498

http://www.w3.org/2001/XMLSchema#string

P698

25668262

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4349346

http://www.w3.org/2001/XMLSchema#string